Homeopathic Pharmaceuticals / Alternative Medicine
Strategic Profile
In 2025, Boiron had annual revenue of 501.11M EUR with 2.78% growth, demonstrating modest stability in a mature market. The company maintained a gross profit margin of 73.6% in the most recent fiscal year, reflecting strong cost management in homeopathic product manufacturing and distribution.
Cyborg Score Rationale
Boiron dominates the global homeopathy market with high margins and consistent profitability, but faces headwinds from modest revenue growth, margin compression from prior years, and declining sales momentum as alternative medicine adoption slows in developed markets.
Top Insights
Global homeopathy market leader with ~€501M revenue as of 2025, but growth slowing to 2.78% year-over-year
In 2024, Boiron generated approximately €280M in turnover outside of France, indicating strong international diversification but with flat-to-negative growth trends
Gross margins of 73.6% demonstrate pricing power and operational efficiency in manufacturing, though operational expenses are rising
Market capitalization of $566M as of late May 2026, valuing the company at approximately 1.0x trailing revenue
Named Competitors
Homeopathic Products — French homeopathic manufacturer
Pharmaceutical Products — Generic and specialty pharmaceuticals
Recent Developments
(February 2026) Corporate deal with Panaxia Pharmaceutical Industries
(2025) Annual revenue of €501.11M with 2.78% growth, representing deceleration from prior year
(December 2024) Last 12-month revenue of €504.86M with declining year-over-year growth momentum
Open the full interactive Boiron Group (Boiron SA) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.